江汉大学学报:自然科学版
江漢大學學報:自然科學版
강한대학학보:자연과학판
Journal of Jianghan University:Natural Sciences
2011年
4期
71-72,76
,共3页
刘文%全卓勇%崔军凯%冯燕%邵永胜%张应天
劉文%全卓勇%崔軍凱%馮燕%邵永勝%張應天
류문%전탁용%최군개%풍연%소영성%장응천
结直肠癌%淋巴结%转移%出芽%预后
結直腸癌%淋巴結%轉移%齣芽%預後
결직장암%림파결%전이%출아%예후
colorectal cancer%lymph node%metastasis%budding%prognosis
目的:研究结直肠癌中肿瘤出芽与淋巴结分期及预后的关系.方法:2004年1月-2009年12月有完整淋巴结病理学资料的结直肠癌手术患者112例,全数淋巴结检查,参照Ueno等的研究判断肿瘤出芽.结果:本组切除淋巴结3 809枚,平均每例取约34枚,112例结直肠癌中有51例出芽.肿瘤出芽与淋巴结转移的程度呈显著性相关.无肿瘤出芽的61例5年生存率为82.54%,有肿瘤出芽的51例5年生存率为31.45%.结论:在判断结直肠癌预后和选择术后辅助治疗方案方面,肿瘤出芽和淋巴结转移的检测同等重要.
目的:研究結直腸癌中腫瘤齣芽與淋巴結分期及預後的關繫.方法:2004年1月-2009年12月有完整淋巴結病理學資料的結直腸癌手術患者112例,全數淋巴結檢查,參照Ueno等的研究判斷腫瘤齣芽.結果:本組切除淋巴結3 809枚,平均每例取約34枚,112例結直腸癌中有51例齣芽.腫瘤齣芽與淋巴結轉移的程度呈顯著性相關.無腫瘤齣芽的61例5年生存率為82.54%,有腫瘤齣芽的51例5年生存率為31.45%.結論:在判斷結直腸癌預後和選擇術後輔助治療方案方麵,腫瘤齣芽和淋巴結轉移的檢測同等重要.
목적:연구결직장암중종류출아여림파결분기급예후적관계.방법:2004년1월-2009년12월유완정림파결병이학자료적결직장암수술환자112례,전수림파결검사,삼조Ueno등적연구판단종류출아.결과:본조절제림파결3 809매,평균매례취약34매,112례결직장암중유51례출아.종류출아여림파결전이적정도정현저성상관.무종류출아적61례5년생존솔위82.54%,유종류출아적51례5년생존솔위31.45%.결론:재판단결직장암예후화선택술후보조치료방안방면,종류출아화림파결전이적검측동등중요.
Objective:To study the relationship of tumor budding with lymph node staging and prognosis in colorectal cancer. Methods:We analyzed 112 patients with colorectal cancer who hadreceived operation and with complete pathologic data of lymph node from January 2004 to Decem- ber 2009. All lymph nodes collected from these patients were examined. Tumor budding was identified according to the method mentioned by Ueno and his colleagues. Results:In total, 3809 lymph nodes were dissected from 112 patients, the average number is 34 lymph nodes per patient. Tumor budding were detected in 51 colorectal cancer patients. Strong correlation was found between tumor budding and the ratio of lymph node metastasis. Five years cumulative survival of 61 patients without tumor budding is 82.54%, and five years cumulative survival of 51 patients with tumor budding is 31.45%. Conclusion:Tumor budding is important equal to lymph node metastasis to predict the prognosis and guide postoperative assistant therapy in colorectal cancer.